Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.
about
Inhibition of histone deacetylases in cancer therapy: lessons from leukaemiaProfiling technologies for the identification and characterization of small-molecule histone deacetylase inhibitorsA Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug NetworkNovel Strategies to Improve the Endocrine Therapy of Breast Cancer.HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer.Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ ExpressionExpression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significanceHigh nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients.Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the BreastIdentification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases.The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancerDNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells.Histone deacetylase 10 suppresses proliferation and invasion by inhibiting the phosphorylation of β-catenin and serves as an independent prognostic factor for human clear cell renal cell carcinoma.β-Bisabolene, a Sesquiterpene from the Essential Oil Extract of Opoponax (Commiphora guidottii), Exhibits Cytotoxicity in Breast Cancer Cell Lines.Microarray gene expression profiling reveals potential mechanisms of tumor suppression by the class I HDAC-selective benzoylhydrazide inhibitors.Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer.Downregulation of the Ca(2+)-activated K(+) channel KC a3.1 by histone deacetylase inhibition in human breast cancer cellsHistone deacetylases and mechanisms of regulation of gene expressionOverexpression of caspase 7 is ERα dependent to affect proliferation and cell growth in breast cancer cells by targeting p21(Cip).A potential adjuvant chemotherapeutics, 18β-glycyrrhetinic acid, inhibits renal tubular epithelial cells apoptosis via enhancing BMP-7 epigenetically through targeting HDAC2.Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.Epigenetic changes: a common theme in acute myelogenous leukemogenesisInhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance.Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLCInhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression.PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.Epigenetic reprogramming in breast cancer: from new targets to new therapies.Histone deacetylase inhibitors in oral squamous cell carcinoma treatment.Histone deacetylase inhibitors in hematological malignancies and solid tumors.Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.The role of REST and HDAC2 in epigenetic dysregulation of Nav1.5 and nNav1.5 expression in breast cancer.Entinostat: a promising treatment option for patients with advanced breast cancer.HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.HDACs and HDAC Inhibitors in Cancer Development and Therapy.Transcriptional repression of ER through hMAPK dependent histone deacetylation by class I HDACs.HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
P2860
Q26767024-C0AC65B7-05E1-40F2-A458-3416D914CE81Q28079587-F1072A7E-FB23-4E8F-A39B-9F6CA75A70EEQ28817426-910799F0-FB35-4477-B254-59AECFC19449Q33727284-BDE7E68B-E559-4791-AB04-87B6D91351D1Q33733042-6B051B2F-179E-4806-AB3D-D5ECAC143886Q33755131-7472011A-06DF-4017-B9FA-CCBEC301117AQ33970364-7535D648-54E0-42A4-8C7E-1B022533871FQ34107754-DA784231-599C-4E5E-8DC2-47E613C809D8Q34371426-66104A14-FB9D-4D58-9F2D-6AF7C9C2AA66Q34602263-125C767D-04C6-4281-9817-E274AD8F3B7FQ34779627-0BDC743A-43DE-493A-A9E3-15015426F303Q35194759-F59393C5-2618-40B3-976E-043AB83E46F9Q35238263-228EEA24-DCC9-413D-8AA0-20932059DF22Q35492725-3D38FE66-C7E2-4DDC-A34C-88E833CD28D3Q35643696-B8959116-A8DE-4F08-BE12-52C51EEC85E1Q35868431-87EEBD02-BA8B-4D0F-8390-F4F40E677917Q35884595-C4C9EB12-38A6-44A8-BC16-97CA778E42E6Q36413835-D2AB2E0B-1736-474F-BF76-833A6EE3036FQ36579794-C5050F62-337D-46D5-BB0F-1B5A69C2D318Q36719626-7AA2A214-FA35-4B88-A3D1-F6DE4F2AC86CQ36734390-70F468F9-DBE3-47F6-8F65-991DA0958CF5Q36846714-DCFB4B19-71D2-4746-9963-DECDD4879518Q36870776-130158CC-D5BD-48F6-ABEF-318D46A27356Q36946516-BF5A849B-97FC-414F-8D41-0A7CD3678043Q36946596-763B3E87-3148-4BE2-B4DD-99A214C5891FQ37116613-B30225DA-4FA2-41CC-894A-21AD25D0F898Q37521291-5C43A96F-AB8F-4AAD-888B-26DA9FB50CF7Q37645002-42580232-9755-44DA-B004-4DE8B8F8DDE4Q37682212-CFEE7C86-6762-4A00-BB76-0E8545F132C4Q37707021-9344F0B6-637C-4B1E-B51C-11E51AE0C70BQ38233472-1D433E71-7A94-445D-A753-BC83B3798609Q38248710-9849907D-56FB-4818-94E8-94389CBD4268Q38344675-04A967E8-F0E9-41EB-A27E-02F54F9D56FDQ38537768-C983BB43-6C6C-4F36-A246-009ED8CA0BB9Q38695555-13463B3C-B9D4-4440-85F7-B3F7DECD8B35Q38741783-66ADEEA2-F570-4214-A41D-C485A3BA3B25Q38885415-D13AF882-045F-4665-B0AE-33A363E6029FQ38947405-CE8C8AFC-7C38-4602-8E4E-30976EA3C6A8Q38965387-4F19CCC4-EBAE-446B-B8E6-A5780795C90EQ39586909-F65F2DB5-C13D-451A-A185-85B6DC98DE63
P2860
Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Differential expression of his ...... cators of disease progression.
@ast
Differential expression of his ...... cators of disease progression.
@en
Differential expression of his ...... cators of disease progression.
@nl
type
label
Differential expression of his ...... cators of disease progression.
@ast
Differential expression of his ...... cators of disease progression.
@en
Differential expression of his ...... cators of disease progression.
@nl
prefLabel
Differential expression of his ...... cators of disease progression.
@ast
Differential expression of his ...... cators of disease progression.
@en
Differential expression of his ...... cators of disease progression.
@nl
P2093
P2860
P50
P356
P1433
P1476
Differential expression of his ...... cators of disease progression.
@en
P2093
Annika Lehmann
Atsuko Kasajima
Carsten Denkert
Jan Budczies
Judith Prinzler
Klaus-Jürgen Winzer
P2860
P2888
P356
10.1186/1471-2407-13-215
P407
P577
2013-04-30T00:00:00Z
P5875
P6179
1004045936